FAQ: Soligenix's HyBryte™ Therapy for Cutaneous T-Cell Lymphoma (CTCL)
Summary
Soligenix is advancing HyBryte™ (synthetic hypericin) as a potential first-line treatment for early-stage cutaneous T-cell lymphoma, with promising results from its FLASH trials showing significant efficacy and safety that could reshape CTCL treatment standards.
What is HyBryte™ and what condition does it treat?
HyBryte™ (also known as SGX301) is a novel photodynamic therapy using synthetic hypericin that treats cutaneous T-cell lymphoma (CTCL), specifically targeting early-stage forms of this rare cancer.
What results have been shown in the clinical trials for HyBryte™?
In the original FLASH study, nearly half of patients showed meaningful response at 18 weeks, and interim results from an independent University of Pennsylvania study reported a 75% response rate, demonstrating statistically significant efficacy and safety.
Why is HyBryte™ considered significant for CTCL treatment?
HyBryte™ could become the first approved front-line therapy for early-stage CTCL, reshaping standards of care in a field where therapeutic innovation has lagged and offering new hope for patients.
How does HyBryte™ work as a treatment?
HyBryte™ is a non-UV light-activated therapy that uses synthetic hypericin as a novel photodynamic therapy, utilizing safe visible light to treat CTCL lesions.
What is the current status of HyBryte™ development?
Soligenix is continuing development with the ongoing FLASH 2 confirmatory study, which builds on previous FLASH trial findings while addressing regulatory requirements for confirmatory evidence needed for potential commercialization.
What other conditions is Soligenix developing treatments for?
Beyond CTCL, Soligenix is developing synthetic hypericin for psoriasis, dusquetide for inflammatory diseases including oral mucositis, and has vaccine programs for ricin toxin, filoviruses (Marburg and Ebola), and COVID-19 (CiVax™).
Where can I find more information about Soligenix and its developments?
For further information, visit the company’s website at www.Soligenix.com or access the latest news and updates at https://ibn.fm/SNGX.
What makes Soligenix’s approach to vaccine development unique?
Soligenix’s vaccine programs incorporate its proprietary heat stabilization platform technology called ThermoVax®, which has been supported by government grants and contracts from NIAID, DTRA, and BARDA.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 264403